Combination therapy with atezolizumab and bevacizumab resulted in an increase in CD8 + T cells and major histocompatibility complex 1 in the tumor, as well as up-regulation of chemokines and down-regulation of genes associated with neovascularization in patients with metastatic RCC [125]. The gene discussed is CD8A; the disease is neoplasm.